STOCK TITAN

Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Waters Corporation (NYSE:WAT) has launched BioResolve Protein A Affinity Columns with MaxPeak Premier Technology, marking their first entry into affinity chromatography columns. The innovative product delivers up to 7x improvement in sensitivity compared to market leaders, featuring novel non-porous 3.5 μm particles. Key benefits include: enabling measurements up to 2 days earlier for antibody titers, providing 2x more attribute information with simplified workflows, and allowing accurate quantitation at lower concentrations with less sample. The columns, available in 2.1 x 20 mm and 3.9 x 5 mm formats, can be coupled with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system.
Waters Corporation (NYSE:WAT) ha lanciato le colonne di affinità BioResolve Protein A con la tecnologia MaxPeak Premier, segnando il loro primo ingresso nel settore delle colonne per cromatografia di affinità. Questo prodotto innovativo offre un miglioramento della sensibilità fino a 7 volte rispetto ai leader di mercato, grazie a nuove particelle non porose da 3,5 μm. I principali vantaggi includono: la possibilità di effettuare misurazioni fino a 2 giorni prima per i titoli anticorpali, fornendo il doppio delle informazioni sugli attributi con flussi di lavoro semplificati, e consentendo una quantificazione accurata a concentrazioni più basse con meno campione. Le colonne, disponibili nei formati 2,1 x 20 mm e 3,9 x 5 mm, possono essere abbinate a colonne per cromatografia di esclusione dimensionale per misurare concentrazioni di titolo e analisi degli aggregati in un'unica corsa su qualsiasi sistema LC.
Waters Corporation (NYSE:WAT) ha lanzado las columnas de afinidad BioResolve Protein A con la tecnología MaxPeak Premier, marcando su primera incursión en columnas de cromatografía de afinidad. Este producto innovador ofrece una mejora de sensibilidad de hasta 7 veces en comparación con los líderes del mercado, con partículas novedosas no porosas de 3,5 μm. Los beneficios clave incluyen: permitir mediciones hasta 2 días antes para títulos de anticuerpos, proporcionar el doble de información de atributos con flujos de trabajo simplificados y permitir una cuantificación precisa a concentraciones más bajas con menos muestra. Las columnas, disponibles en formatos de 2,1 x 20 mm y 3,9 x 5 mm, pueden combinarse con columnas de cromatografía de exclusión por tamaño para medir concentraciones de títulos y análisis de agregados en una sola corrida en cualquier sistema LC.
Waters Corporation(NYSE:WAT)는 MaxPeak Premier 기술이 적용된 BioResolve Protein A 친화성 컬럼을 출시하며 친화성 크로마토그래피 컬럼 시장에 첫 진출을 알렸습니다. 이 혁신적인 제품은 시장 선도 제품 대비 감도 최대 7배 향상을 제공하며, 새로운 비다공성 3.5 μm 입자를 특징으로 합니다. 주요 장점으로는 항체 역가 측정을 최대 2일 앞당길 수 있고, 간소화된 워크플로우로 2배 더 많은 속성 정보를 제공하며, 적은 시료로 낮은 농도에서도 정확한 정량이 가능하다는 점이 있습니다. 2.1 x 20 mm 및 3.9 x 5 mm 형식으로 제공되는 이 컬럼들은 크기 배제 크로마토그래피 컬럼과 결합하여 모든 LC 시스템에서 단일 분석으로 역가 농도 및 응집체 분석을 수행할 수 있습니다.
Waters Corporation (NYSE:WAT) a lancé les colonnes d'affinité BioResolve Protein A avec la technologie MaxPeak Premier, marquant ainsi leur première incursion dans les colonnes de chromatographie d'affinité. Ce produit innovant offre une amélioration de la sensibilité jusqu'à 7 fois par rapport aux leaders du marché, grâce à de nouvelles particules non poreuses de 3,5 μm. Les principaux avantages incluent : permettre des mesures jusqu'à 2 jours plus tôt pour les titres d'anticorps, fournir deux fois plus d'informations sur les attributs avec des flux de travail simplifiés, et permettre une quantification précise à des concentrations plus faibles avec moins d'échantillon. Les colonnes, disponibles en formats 2,1 x 20 mm et 3,9 x 5 mm, peuvent être associées à des colonnes de chromatographie d'exclusion de taille pour mesurer les concentrations de titres et effectuer une analyse des agrégats en une seule course sur n'importe quel système LC.
Waters Corporation (NYSE:WAT) hat die BioResolve Protein A Affinitäts-Säulen mit MaxPeak Premier Technologie auf den Markt gebracht und damit ihren ersten Schritt im Bereich der Affinitätschromatographiesäulen gemacht. Das innovative Produkt bietet eine bis zu 7-fach verbesserte Empfindlichkeit im Vergleich zu Marktführern und verfügt über neuartige, porenfreie 3,5 μm Partikel. Zu den wichtigsten Vorteilen zählen: Messungen von Antikörpertitern bis zu 2 Tage früher zu ermöglichen, doppelt so viele Attributinformationen mit vereinfachten Arbeitsabläufen bereitzustellen und eine genaue Quantifizierung bei niedrigeren Konzentrationen mit weniger Probenmaterial zu erlauben. Die Säulen sind in den Formaten 2,1 x 20 mm und 3,9 x 5 mm erhältlich und können mit Größenausschlusschromatographiesäulen kombiniert werden, um Titermessungen und Aggregatanalysen in einem einzigen Lauf auf jedem LC-System durchzuführen.
Positive
  • Up to 7x improvement in sensitivity compared to market leaders
  • Enables measurements up to 2 days earlier for antibody titers
  • Delivers 2x more attribute information with simplified workflows
  • Can analyze samples without prior purification, reducing processing time
  • First entry into affinity chromatography columns market, expanding product portfolio
Negative
  • None.

Insights

Waters' new Protein A columns significantly improve antibody analysis speed and sensitivity, strengthening their position in the growing biologics market.

Waters Corporation has launched BioResolve Protein A Affinity Columns with MaxPeak Premier Technology, representing their first entry into the affinity chromatography column market. This strategic product expansion directly addresses critical bottlenecks in biotherapeutic development.

The technical specifications are impressive: the columns enable antibody titer measurements up to 2 days earlier than current methods, provide up to 7x improvement in sensitivity compared to market leaders, and deliver 2x more attribute information through simplified multi-attribute workflows. The technology uses novel non-porous 3.5 μm particles that allow accurate quantitation at lower concentrations with reduced sample volumes.

This innovation is particularly significant for the rapidly growing monoclonal antibody market. By accelerating cell line identification and optimization, Waters is addressing a major pain point in biologics development. The columns' ability to couple with size exclusion chromatography for simultaneous titer concentration and aggregate analysis in a single run represents meaningful workflow efficiency.

The testimonial from Quality Assistance's R&D Director highlights the product's practical benefits in streamlining two-dimensional workflows and enabling LC/MS integration without prior sample purification. This validation from an industry partner suggests genuine utility rather than merely incremental improvement.

Waters is strategically positioning this product within their broader biologics analysis portfolio, reinforcing their commitment to the high-value biotherapeutics market. This launch strengthens Waters' competitive position against other analytical instrument providers in the lucrative and growing biologics segment, potentially capturing additional market share in bioprocessing workflows.

News Summary

  • Enables measurements up to 2 days earlier for antibody titers for both clone selection and bioprocess monitoring.1
  • Provides up to 7x improvements in sensitivity with novel high efficiency particles.2
  • Delivers 2x more attribute information with simplified multi-attribute workflows.3

MILFORD, Mass., May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements. This launch marks the first set of affinity chromatography columns that Waters has brought to market, in a groundbreaking move as the Company continues to release new products that solve unmet needs in large molecule separations. The new columns enable earlier access to results in upstream bioprocessing, faster method optimization in downstream development for biologics, and a new level of agility in the discovery, optimization, and manufacturing of antibody-based drug products.  

Waters introduces the most sensitive protein A column on the market, bringing lifesaving therapies to patients, faster.

"Today's launch of the BioResolve Protein A Affinity Columns will help to bring lifesaving therapies to patients, faster. One of the main bottlenecks in the development of biotherapeutics like monoclonal antibodies is the time required to identify and optimize a suitable cell line for antibody production," said Dr. Udit Batra, President and Chief Executive Officer, Waters Corporation. "We have solved for this by designing a novel, highly efficient particle with an immobilized Protein A surface, and combined this with MaxPeak Premier Hardware, resulting in the most sensitive protein A column on the market."  

The BioResolve Protein A Affinity Columns have been designed to provide up to 7x improvements in sensitivity compared to the market leader. The novel, non-porous 3.5 μm particles allow accurate quantitation of antibody titers at lower concentrations and with less sample. In addition, the columns have been designed to couple with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system.

"The new column will enhance our ability to support our clients in developing new medicines," said Arnaud Delobel, R&D and Innovation Director, Quality Assistance. "It simplifies two-dimensional workflows for simultaneous titer and aggregate analysis, and can be readily integrated into new LC/MS setups to analyze in-process antibody samples without prior purification. By streamlining workflows and enabling simultaneous assessment of multiple critical quality attributes, it helps cut project turnaround times and ultimately supports faster time to market for biologics."

This innovation furthers the Company's commitment to enhancing the analytical toolbox for biomolecule characterization, allowing scientists to speed up the development of safe, efficacious, and accessible biotherapeutics.

The columns are available in 2.1 x 20 mm and 3.9 x 5 mm formats and are available to order now.

Additional Resources: See application notes and specifications at www.Waters.com/affinity

ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Waters, BioResolve, and MaxPeak are trademarks of Waters Technologies Corporation.

Contact:

Molly Gluck
Head of External Communications
Waters Corporation
Molly_gluck@waters.com
Mobile: +1.617.833.8166

  1. Improved ability to detect antibody at 7x lower concentrations using low-dispersion U(H)PLC allows for titer measurements at least one day earlier based on standard CHO cell line doubling time.
  2. Application note 720008775EN: In a well-controlled experiment, the lower limit of quantitation of NISTmAb reference material RM 8671 was 5x-7x lower using the 2.1 x 20 mm and 3.9 x 5 mm BioResolve Protein A Affinity Columns using a low-dispersion UPLC compared to a leading competitor.
  3. Application note 720008780EN: Demonstrates the measurement of antibody titer and aggregate analysis in a single run following a direct-connect ProA-SEC method.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-introduces-bioresolve-protein-a-affinity-columns-to-accelerate-antibody-titer-measurement-enhancing-process-agility-and-batch-quality-302466477.html

SOURCE Waters Corporation

FAQ

What are the key features of Waters' new BioResolve Protein A Affinity Columns (WAT)?

The columns feature MaxPeak Premier Technology, provide 7x improved sensitivity, enable measurements up to 2 days earlier, and deliver 2x more attribute information with simplified workflows. They use novel non-porous 3.5 μm particles for accurate quantitation at lower concentrations.

How does Waters' BioResolve Protein A column improve bioprocessing efficiency?

It enables earlier access to results in upstream bioprocessing, allows faster method optimization in downstream development, and provides simultaneous titer and aggregate analysis in a single run, significantly reducing processing time.

What sizes are available for Waters' BioResolve Protein A Affinity Columns?

The columns are available in two formats: 2.1 x 20 mm and 3.9 x 5 mm.

How does Waters' new Protein A column benefit biotherapeutics development?

It accelerates cell line identification and optimization for antibody production, enables analysis without prior purification, and streamlines workflows for multiple critical quality attributes assessment, supporting faster time to market for biologics.
Waters

NYSE:WAT

WAT Rankings

WAT Latest News

WAT Latest SEC Filings

WAT Stock Data

20.63B
59.42M
0.08%
96.91%
2.72%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
MILFORD